The antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) were compared with those of five similar compounds and four comparison drugs against 103 strains of LegioneUa pneumophila and five other LegioneUla species type strains. When concentrations inhibiting 90%o of strains tested (MIC90s) for L. pneumophila were determined, CI-960 and temafloxacin emerged as the most active (0.015 pg/ml) and were followed in potency by E4695 (0.03 pg/mi). This activity was two-to fourfold greater than that of the reference drug, ciprofloxacin, and approached that of rifampin (MIC90, 0.008 pg/ml). All fluoroquinolones studied were more active than erythromycin (MIC90, 0.5 ,jLg/ml). These two investigational fluoroquinolones appear well suited for further in vivo study of legionellosis therapy.
For more than 15 years, Legionella pneumophila has been recognized as a significant cause of lower respiratory infections (4). Because Legionella species are able to live and replicate intracellularly, therapeutic antimicrobial agents that penetrate bacterial cell walls and high intracellular concentrations are required (6) . Of the comparison compounds tested in this and other studies, rifampin and erythromycin have been the drugs of choice, maintaining good in vitro and in vivo activities against Legionella species (1, 4, 5, 7, 8, 10, 14) .
In this study, the testing procedures used the buffered starch-yeast extract agar and broth medium described by Sawatari et al. (14) . This medium contains no charcoal, which has been observed to inactivate some anti-Legionella drugs (1, 10 penem from the Merck Institute (Rahway, N.J.), E4695 from Laboratories Dr. Esteve (Barcelona, Spain), and rifampin from Marion Merrell-Dow (Kansas City, Mo.). The antimicrobial agents were diluted in buffered starch-yeast extract agar (14) , and the isolates were inoculated at a concentration of 106 CFU per spot. Agar plates were incubated in ambient air for 48 h. Endpoint criteria recommended by the National Committee for Clinical Laboratory Standards (13) were used for interpretation of MICs.
The fluoroquinolones and four comparison antimicrobial agents were tested in charcoal-free buffered starch-yeast extract agar (Table 1 ). The seven fluoroquinolones were generally quite potent (MICs, <0.12 ,ug/ml) against the L. pneumophila strains. The activity rank order of the fluoroquinolones was as follows: CI-960 (MIC for 90% of strains tested [MIC0], 0.015 p,g/ml) = temafloxacin > E4695 > ciprofloxacin = fleroxacin = ofloxacin > lomefloxacin (MIC90, 0.06 ,ug/ml). Among the three investigational compounds, CI-960 was the most potent, having all MICs between 0.004 and 0.015 ,ug/ml. The fluoroquinolones were generally more potent than the other comparison compounds, tetracycline (MIC90, 8 p,g/ml) and imipenem (MICg, 1 ,ug/ml). The macrolide comparison agent, erythromycin, also exhibited activity against these isolates (MIC90, 0.5 ,ug/ml). Rifampin MICs ranged from .0.002 to 0.03 ,ug/ml, i.e., it was the most potent drug tested. The activity of temafloxacin against L. pneumophila was superior to that of ciprofloxacin, confirming the results of an earlier study (7) .
These compounds were very active against five representative strains of four other Legionella spp. (Table 2 lower than that of ciprofloxacin (12) . The anti-Legionella potencies of these fluoroquinolones were also assessed as inferior (5) to ciprofloxacin and/or rifampin.
The activities of the fluoroquinolones and macrolides can be enhanced by intracellular accumulation (3) . Since legionellae are intracellular pathogens, it is necessary that clinically effective antimicrobial agents be readily transferred into phagocytes (6) . Reports have previously documented that discrepancies in in vitro and in vivo antiLegionella potencies exist between those drugs that remain predominantly in the extracellular space and those that do not (8) . The reported abilities of fluoroquinolones to penetrate the phagocytic cells and also to exhibit significant activities indicate that the least active drug of this class (Table 1) .
There were no differences in the drug potencies of the clinical and the environmental isolates tested, nor were there any over time (10-year sample) . No trends of resistance to the currently used macrolide (erythromycin), rifampin, and tetracycline or to the most active beta-lactam (imipenem) could be identified over the time period in which samples were obtained in this study.
Among the potential therapeutic agents tested, the fluoroquinolones should be considered strong candidates, with the newer agents CI-960 (2) and E4695 (11) worthy of further in vivo investigations.
